BMO Capital analyst Evan Seigerman upgraded Replimune (REPL) to Market Perform from Underperform with a price target of $11, up from $2. The firm says current share levels “reflect appropriate risk” for the company’s RP1 program. Replimune seems to have better alignment with regulators on a path forward for the drug, the analyst tells investors in a research note. BMO says Replimune’s “productive” Type A meeting supports potential approval.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REPL:
- Replimune’s Promising Study on Metastatic Uveal Melanoma: A Potential Game Changer?
- Replimune’s RP2 Study: A Promising Step in Cancer Immunotherapy
- Replimune’s Phase 3 Study on Advanced Melanoma: A Potential Game-Changer?
- Replimune’s Innovative Cancer Therapy: A Phase 1 Study Update
- Replimune’s RP1 Study: A Promising Update for Transplant Patients with Skin Cancer